United Kingdom

People: Cyclacel Pharmaceuticals Inc (CYCC.OQ)

CYCC.OQ on NASDAQ Stock Exchange Capital Market

3:48pm BST
Change (% chg)

$-0.02 (-4.68%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Chiao, Judy 

Dr. Judy H. Chiao, M.D., serves as Vice President - Clinical Development and Regulatory Affairs of Cyclacel Pharmaceuticals Inc., Dr. Chiao joined Cyclacel in December 2004. From December 2001 to September 2004, she was employed at Aton Pharma, Inc., a wholly owned subsidiary of Merck & Co. Inc., most recently as Vice President, Oncology Clinical Research and Development. Prior to Aton’s acquisition by Merck, she was responsible for leading the clinical development of Zolinza®, a histone deacetylase inhibitor, for hematologic and solid tumor indications. From July 2000 to December 2001, Dr. Chiao was a Senior Medical Reviewer, Division of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, where she was the agency’s primary reviewer for a range of oncology drugs and regulatory subjects. She also presented the FDA’s views in several New Drug Application reviews at Oncology Drug Advisory Committees. Dr. Chiao earned her Bachelor of Science in Chemistry (summa cum laude) at Columbia University and received her medical degree from Harvard Medical School. Her internship and residency in internal medicine was carried out at Columbia-Presbyterian Medical Center, New York and she held a Research Fellowship in Molecular Pharmacology at Sloan Kettering Institute for Cancer Research and a Clinical Fellowship in Hematology/Oncology at Memorial Sloan Kettering Cancer Center, both in New York. She has also been a member of a number of FDA-related working groups and has also been a Core Member of the Pharsight-FDA Cooperative Research and Development Agreement (CRADA) on clinical trial simulation and population pharmacokinetic analysis software for drug development.

Basic Compensation

Total Annual Compensation, USD 445,925
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 142,747
Fiscal Year Total, USD 588,672

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --